Tumor sidedness and efficacy of first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer: A network meta-analysis

Chih Chien Wu; Jui Ho Wang; Pei Chin Lin; Chun An Liang; Ching Ying Huang; Han Chu Lien; Chung Yu Chen; Kang Ju Chou; Yi Chia Su

doi:10.1016/j.critrevonc.2019.102823

Tumor sidedness and efficacy of first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer: A network meta-analysis

Chih Chien Wu, Jui Ho Wang, Pei Chin Lin, Chun An Liang, Ching Ying Huang, Han Chu Lien, Chung Yu Chen, Kang Ju Chou, Yi Chia Su^*

^*Corresponding author for this work

Department of Internal Medicine

Research output: Contribution to journal › Review article › peer-review

19 Scopus citations

Abstract

We conducted a systemic search of several databases for randomized controlled trials (RCTs) that reported efficacy and safety outcomes of drugs for left-sided and right-sided metastatic colorectal cancer (mCRC), to identify the best available treatment. A network meta-analysis with mixed comparisons was created to interpret the best treatment option using the surface under the cumulative ranking curve. In the left-sided rat sarcoma (RAS) wild-type (WT) mCRC patients, bevacizumab, panitumumab, or cetuximab with chemotherapy groups showed a significantly better objective response rate than the chemotherapy alone group. The progression-free survival (PFS) and overall survival were better with panitumumab or cetuximab with chemotherapy than with chemotherapy alone. In the right-sided RAS WT mCRC patients, PFS for bevacizumab with chemotherapy was significantly better than that for cetuximab with chemotherapy. Cetuximab, closely followed by panitumumab, is the most effective treatment in left-sided RAS WT mCRC. Bevacizumab is more effective in right-sided mCRC.

Original language	English
Article number	102823
Journal	Critical Reviews in Oncology/Hematology
Volume	145
DOIs	https://doi.org/10.1016/j.critrevonc.2019.102823
State	Published - Jan 2020

Keywords

First-line therapy
Metastatic colorectal cancer
Network meta-analysis
Targeted agents
Tumor sidedness

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.critrevonc.2019.102823

Cite this

Wu, C. C., Wang, J. H., Lin, P. C., Liang, C. A., Huang, C. Y., Lien, H. C., Chen, C. Y., Chou, K. J., & Su, Y. C. (2020). Tumor sidedness and efficacy of first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer: A network meta-analysis. Critical Reviews in Oncology/Hematology, 145, Article 102823. https://doi.org/10.1016/j.critrevonc.2019.102823

@article{63f44a0450dd47d6873d0cdbfc75c2ed,

title = "Tumor sidedness and efficacy of first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer: A network meta-analysis",

abstract = "We conducted a systemic search of several databases for randomized controlled trials (RCTs) that reported efficacy and safety outcomes of drugs for left-sided and right-sided metastatic colorectal cancer (mCRC), to identify the best available treatment. A network meta-analysis with mixed comparisons was created to interpret the best treatment option using the surface under the cumulative ranking curve. In the left-sided rat sarcoma (RAS) wild-type (WT) mCRC patients, bevacizumab, panitumumab, or cetuximab with chemotherapy groups showed a significantly better objective response rate than the chemotherapy alone group. The progression-free survival (PFS) and overall survival were better with panitumumab or cetuximab with chemotherapy than with chemotherapy alone. In the right-sided RAS WT mCRC patients, PFS for bevacizumab with chemotherapy was significantly better than that for cetuximab with chemotherapy. Cetuximab, closely followed by panitumumab, is the most effective treatment in left-sided RAS WT mCRC. Bevacizumab is more effective in right-sided mCRC.",

keywords = "First-line therapy, Metastatic colorectal cancer, Network meta-analysis, Targeted agents, Tumor sidedness",

author = "Wu, {Chih Chien} and Wang, {Jui Ho} and Lin, {Pei Chin} and Liang, {Chun An} and Huang, {Ching Ying} and Lien, {Han Chu} and Chen, {Chung Yu} and Chou, {Kang Ju} and Su, {Yi Chia}",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier B.V.",

year = "2020",

month = jan,

doi = "10.1016/j.critrevonc.2019.102823",

language = "English",

volume = "145",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Tumor sidedness and efficacy of first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer

T2 - A network meta-analysis

AU - Wu, Chih Chien

AU - Wang, Jui Ho

AU - Lin, Pei Chin

AU - Liang, Chun An

AU - Huang, Ching Ying

AU - Lien, Han Chu

AU - Chen, Chung Yu

AU - Chou, Kang Ju

AU - Su, Yi Chia

PY - 2020/1

Y1 - 2020/1

N2 - We conducted a systemic search of several databases for randomized controlled trials (RCTs) that reported efficacy and safety outcomes of drugs for left-sided and right-sided metastatic colorectal cancer (mCRC), to identify the best available treatment. A network meta-analysis with mixed comparisons was created to interpret the best treatment option using the surface under the cumulative ranking curve. In the left-sided rat sarcoma (RAS) wild-type (WT) mCRC patients, bevacizumab, panitumumab, or cetuximab with chemotherapy groups showed a significantly better objective response rate than the chemotherapy alone group. The progression-free survival (PFS) and overall survival were better with panitumumab or cetuximab with chemotherapy than with chemotherapy alone. In the right-sided RAS WT mCRC patients, PFS for bevacizumab with chemotherapy was significantly better than that for cetuximab with chemotherapy. Cetuximab, closely followed by panitumumab, is the most effective treatment in left-sided RAS WT mCRC. Bevacizumab is more effective in right-sided mCRC.

AB - We conducted a systemic search of several databases for randomized controlled trials (RCTs) that reported efficacy and safety outcomes of drugs for left-sided and right-sided metastatic colorectal cancer (mCRC), to identify the best available treatment. A network meta-analysis with mixed comparisons was created to interpret the best treatment option using the surface under the cumulative ranking curve. In the left-sided rat sarcoma (RAS) wild-type (WT) mCRC patients, bevacizumab, panitumumab, or cetuximab with chemotherapy groups showed a significantly better objective response rate than the chemotherapy alone group. The progression-free survival (PFS) and overall survival were better with panitumumab or cetuximab with chemotherapy than with chemotherapy alone. In the right-sided RAS WT mCRC patients, PFS for bevacizumab with chemotherapy was significantly better than that for cetuximab with chemotherapy. Cetuximab, closely followed by panitumumab, is the most effective treatment in left-sided RAS WT mCRC. Bevacizumab is more effective in right-sided mCRC.

KW - First-line therapy

KW - Metastatic colorectal cancer

KW - Network meta-analysis

KW - Targeted agents

KW - Tumor sidedness

UR - http://www.scopus.com/inward/record.url?scp=85075427559&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2019.102823

DO - 10.1016/j.critrevonc.2019.102823

M3 - Review article

C2 - 31783291

AN - SCOPUS:85075427559

SN - 1040-8428

VL - 145

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

M1 - 102823

ER -

Tumor sidedness and efficacy of first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer: A network meta-analysis

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this